Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
42.6M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
33.8M
-
Shares change
-
-1.7M
-
Total reported value, excl. options
-
$112M
-
Value change
-
-$7.68M
-
Put/Call ratio
-
10.41
-
Number of buys
-
26
-
Number of sells
-
-32
-
Price
-
$3.30
Significant Holders of Repare Therapeutics Inc. - Common Shares, no par value (RPTX) as of Q2 2024
79 filings reported holding RPTX - Repare Therapeutics Inc. - Common Shares, no par value as of Q2 2024.
Repare Therapeutics Inc. - Common Shares, no par value (RPTX) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.8M shares
of 42.6M outstanding shares and own 79.4% of the company stock.
Largest 10 shareholders include BVF INC/IL (10.3M shares), Blue Owl Capital Holdings LP (3.37M shares), ORBIMED ADVISORS LLC (3.32M shares), Versant Venture Management, LLC (2.65M shares), ARK Investment Management LLC (2.63M shares), MPM ASSET MANAGEMENT LLC (2.24M shares), Redmile Group, LLC (1.94M shares), MPM BIOIMPACT LLC (1.64M shares), Aquilo Capital Management, LLC (957K shares), and Deep Track Capital, LP (904K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.